Contact

Please use this form to send email to PR contact of this press release:
FDA Filing expected in Q3 for NASDAQ Company’s JW-100 treatment for Eczema; Jupiter Wellness, Inc. (NASDAQ: JUPW)

TO:
JUPW
Jupiter Wellness, Inc
+1 561-244-7100

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.
	SEND EMAIL